This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Disorders of purine and pyrimidine metabolism
E4_PURINEPYRI
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpoints |
205 |
6. Filter based on genotype QC (FinnGen only) |
199 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E70-E90
- Name in latin
- Perturbationes metabolismi purini et pyrimidini
Similar endpoints
↥List of similar endpoints to
Disorders of purine and pyrimidine metabolism
based on the number of shared cases.
Similar with more cases:
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 199 | 76 | 123 |
| Unadjusted period prevalence (%) | 0.05 | 0.03 | 0.06 |
| Median age at first event (years) | 65.55 | 63.57 | 66.77 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 205
- Matched controls
- 2050
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E79.0
ICD-10 Finland
Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease
+∞
224.3
172
*
M04AA01
ATC
allopurinol; systemic
13.8
83.2
121
194
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
13.2
43.6
46
44
M10.9
ICD-10 Finland
Gout, unspecified
10.0
42.2
56
74
M10.0
ICD-10 Finland
Idiopathic gout
10.6
27.2
32
35
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
8.6
20.5
28
37
205
Kela drug reimbursment
Chronic hypertension
3.8
19.6
94
373
M13.9
ICD-10 Finland
Arthritis, unspecified
6.2
19.0
36
68
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.6
18.7
33
58
C03CA01
ATC
furosemide; systemic
3.6
18.3
105
464
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
7.0
18.2
30
49
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.5
17.5
51
140
H02AB06
ATC
prednisolone; systemic
3.6
16.9
135
721
E79.9
ICD-10 Finland
Disorder of purine and pyrimidine metabolism, unspecified
+∞
16.9
16
*
E66.00
ICD-10 Finland
Metabolic syndrome
7.0
15.4
25
40
N17.9
ICD-10 Finland
Acute renal failure, unspecified
12.8
15.3
27
24
212
Kela drug reimbursment
Gout
14.8
15.2
25
19
P01BA02
ATC
hydroxychloroquine; oral
4.9
14.9
37
89
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.1
14.6
47
138
A07EC01
ATC
sulfasalazine; oral, rectal
5.2
14.6
33
73
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
21.1
14.6
21
11
A10BH05
ATC
linagliptin; oral
5.6
14.6
30
61
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
3.9
14.5
52
165
A46
ICD-10 Finland
Erysipelas
3.8
14.5
54
176
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.5
13.8
29
60
E79.8
ICD-10 Finland
Other disorders of purine and pyrimidine metabolism
+∞
13.7
13
*
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
5.9
13.6
26
49
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.5
13.0
27
55
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
53.6
13.0
15
*
I10
ICD-10 Finland
Essential (primary) hypertension
3.2
12.3
154
992
C10AA01
ATC
simvastatin; oral
2.8
12.3
112
609
C03DA01
ATC
spironolactone; oral
3.8
12.2
43
134
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.1
12.1
37
104
H02AB07
ATC
prednisone; oral
3.6
11.9
45
147
288
Kela drug reimbursment
Febuxostat
69.0
11.7
13
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.9
11.6
80
373
C08CA01
ATC
amlodipine; oral
2.8
11.5
106
574
C07AB07
ATC
bisoprolol; oral
2.8
11.3
130
786
J01FF01
ATC
clindamycin; systemic
2.8
11.3
79
371
103
Kela drug reimbursment
Diabetes, insulin-treated
2.8
11.2
78
364
A10BA02
ATC
metformin; oral
2.8
11.2
80
379
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
11.2
60
243
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.9
11.1
70
310
J01DB01
ATC
cefalexin; oral
4.4
10.9
184
1361
L28
ICPC
Limited function/disability (L)
3.0
10.8
59
241
M04AA03
ATC
febuxostat; oral
63.4
10.7
12
*
349
Kela drug reimbursment
Febuxostat
63.4
10.7
12
*
I50.9
ICD-10 Finland
Heart failure, unspecified
3.2
10.7
52
198
C10AA05
ATC
atorvastatin; oral
2.7
10.7
107
598
E66.01
ICD-10 Finland
Obesity due to excess calories
4.7
10.7
26
61
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.2
10.5
30
80
N19
ICD-10 Finland
Unspecified kidney failure
8.9
10.1
21
26
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
9.9
119
717
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.8
9.8
33
99
L04AX03
ATC
methotrexate; systemic
3.7
9.7
34
105
T90
ICPC
Diabetes non-insulin dependent
2.7
9.6
66
303
N18.8
ICD-10 Finland
Other chronic renal failure
11.5
9.5
17
16
AN1
HP
Coronary angiography
3.5
9.4
36
118
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.7
9.2
66
309
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.7
9.1
66
311
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
19.7
9.1
13
7
G47.3
ICD-10 Finland
Sleep apnoea
2.7
9.0
64
298
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
8.8
52
220
E86
ICD-10 Finland
Volume depletion
52.3
8.8
10
*
M01AB01
ATC
indometacin; systemic, rectal
3.6
8.6
31
97
C02AC05
ATC
moxonidine; oral
5.0
8.5
19
41
I50.0
ICD-10 Finland
Congestive heart failure
3.7
8.4
29
88
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.5
8.4
31
99
R50.9
ICD-10 Finland
Fever, unspecified
2.9
8.4
44
174
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
4.7
8.4
20
46
A10BK01
ATC
dapagliflozin; oral
4.2
8.2
23
60
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.1
8.2
37
134
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
7.8
8.2
18
25
A02BC02
ATC
pantoprazole; systemic
2.6
8.2
155
1113
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
8.2
85
470
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
4.0
8.0
24
66
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.0
8.0
40
154
WX722
NOMESCO Finland
PEEP
4.2
7.9
22
57
E66.8
ICD-10 Finland
Other obesity
7.6
7.7
17
24
C09CA03
ATC
valsartan; oral
3.4
7.6
29
94
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
3.1
7.6
34
122
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.9
7.5
23
64
JFA15
NOMESCO Finland
Endoscopic polypectomy in colon
3.8
7.5
24
69
A10AC01
ATC
insulin (human); parenteral
3.7
7.5
25
74
E0000UV, ,
ATC
2.3
7.4
92
543
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
9.9
7.4
14
15
M10
ICD-10 Finland
Gout
4.6
7.4
18
42
A10AB05
ATC
insulin aspart; parenteral
3.8
7.4
24
70
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
7.3
44
186
JN3AD
NOMESCO Finland
Abdominal CT examination
3.2
7.2
31
109
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
10.6
7.1
13
13
R60.0
ICD-10 Finland
Localized oedema
2.9
7.1
36
139
E66.9
ICD-10 Finland
Obesity, unspecified
8.0
7.0
15
20
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.7
7.0
44
191
A11CC03
ATC
alfacalcidol; systemic
11.5
6.9
12
11
A10AE05
ATC
insulin detemir; parenteral
4.2
6.9
19
49
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
2.5
6.8
51
240
E87.5
ICD-10 Finland
Hyperkalaemia
41.5
6.8
8
*
L01BA01
ATC
methotrexate; systemic
6.8
6.8
16
25
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.5
6.8
50
234
N02AX02
ATC
tramadol; systemic, rectal
2.2
6.8
102
645
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
2.7
6.4
37
153
E000001, ,
ATC
2.4
6.4
50
240
C08CA13
ATC
lercanidipine; oral
2.7
6.4
39
166
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
5.4
6.4
18
36
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
2.3
6.3
62
328
N17.8
ICD-10 Finland
Other acute renal failure
18.7
6.3
9
5
I25.1
ICD-10 Finland
Atherosclerotic heart disease
2.3
6.2
57
293
N02AA05
ATC
oxycodone; systemic
2.4
6.2
51
250
R06.0
ICD-10 Finland
Dyspnoea
2.2
6.2
69
385
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
7.1
6.1
14
21
JN4AD
NOMESCO Finland
Body CT examination
2.9
6.1
30
114
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.8
6.0
19
54
A10AE04
ATC
insulin glargine; parenteral
3.1
6.0
26
91
N06AX21
ATC
duloxetine; oral
3.1
6.0
27
97
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
136
428
7.47
45.33
5.8
2.5
418.28
6556.93
umol/l
1.75
123
362
82
157
8.04
45.19
10.2
5.6
1.12
1.03
mmol/l
1.38
77
139
148
788
4.16
19.76
14.8
6.1
1.19
1.21
mmol/l
1.12
122
675
45
102
5.37
19.61
8.1
3.0
105.82
81.24
ng/l
0.95
40
90
72
238
4.12
19.51
4.6
2.0
2.22
2.31
g/l
0.61
66
223
140
724
3.94
19.38
13.6
5.5
1.20
1.21
mmol/l
0.73
129
653
70
228
4.14
19.34
4.7
2.1
20.44
23.53
%
0.99
61
197
74
265
3.80
17.66
4.7
2.0
11.28
13.49
umol/l
1.80
68
245
43
105
4.92
17.07
2.3
1.6
—
—
—
0
0
68
235
3.83
17.03
4.5
3.7
0.79
0.82
mmol/l
1.89
61
219
133
706
3.52
16.80
7.8
4.3
33.31
35.58
g/l
3.96
128
650
119
602
3.33
16.05
2.9
2.0
73.07
76.97
nmol/l
0.75
109
527
49
147
4.07
14.83
9.0
3.5
1.61
1.98
mmol/l
0.21
36
121
32
76
4.80
12.99
2.1
1.8
1.69
1.46
g/l
0.53
27
63
147
909
3.18
12.91
13.2
9.7
4.54
4.05
e9/l
1.93
133
814
68
275
3.20
12.89
2.1
1.9
—
—
—
0
0
95
469
2.91
12.58
2.5
2.0
141.64
179.55
u/l
0.77
88
437
24
46
5.78
12.34
1.5
1.2
—
—
—
0
0
134
803
2.93
12.16
19.5
14.3
1.30
1.31
inr
0.04
31
234
117
655
2.83
12.06
2.6
2.0
75.69
95.88
pmol/l
6.28
74
356
55
204
3.32
11.94
1.8
1.8
—
—
—
0
0
151
983
3.04
11.42
8.8
4.6
7.39
6.81
mmol/l
1.96
143
916
54
207
3.18
11.03
1.7
1.7
—
—
—
0
0
52
198
3.18
10.72
10.8
7.9
1.18
1.20
mmol/l
0.01
38
157
94
498
2.64
10.40
5.9
3.6
27.20
4.98
mg/mmol
2.69
72
302
20
38
5.72
10.34
1.6
1.2
—
—
—
0
0
42
145
3.39
10.12
2.8
2.5
3.05
7.25
ug/l
1.66
33
131
107
615
2.55
9.85
5.7
2.9
—
—
—
0
0
51
201
3.05
9.85
11.0
7.7
5.11
5.15
kpa
0.07
46
188
51
201
3.05
9.85
11.0
7.8
10.50
12.13
kpa
1.15
46
189
136
877
2.64
9.79
8.8
6.6
11.64
11.59
umol/l
0.02
131
821
78
392
2.60
9.45
3.0
2.0
3.97
3.26
mg/l
1.22
68
345
20
42
5.17
9.28
1.3
1.3
—
—
—
0
0
34
108
3.58
9.27
14.0
6.1
89.99
94.09
%
0.77
34
108
94
521
2.49
9.20
3.0
2.4
65.20
65.68
u/l
0.01
89
475
68
323
2.65
9.20
2.0
1.6
1273.95
1173.90
nmol/l
0.36
55
248
30
88
3.82
9.18
1.8
1.3
—
—
—
0
0
94
522
2.48
9.15
6.1
3.1
3145.21
1208.64
ng/l
1.83
83
441
164
1192
2.88
8.75
7.1
4.1
21.38
12.80
mm/h
6.68
157
1089
124
791
2.44
8.74
6.0
3.5
0.00
0.00
estimate
-0.00
34
156
123
783
2.43
8.70
7.7
4.7
0.00
0.00
estimate
-0.00
34
143
57
254
2.72
8.70
1.4
1.3
28.60
13.07
u/ml
0.62
20
101
42
161
3.02
8.43
12.2
9.0
116.71
123.50
g/l
1.09
42
154
124
799
2.40
8.43
6.0
3.6
0.00
0.00
estimate
-0.00
30
141
104
621
2.37
8.43
5.2
2.4
222.74
150.15
ug/l
1.34
92
571
21
53
4.30
7.83
1.9
1.5
—
—
—
0
0
55
258
2.55
7.47
1.5
1.3
43.97
34.64
iu/ml
0.19
20
88
27
87
3.42
7.16
7.4
3.2
56.90
45.45
%
1.58
27
87
80
452
2.26
7.11
6.1
3.8
0.00
0.00
estimate
-0.00
29
133
22
62
3.85
7.09
1.2
1.2
0.22
3.35
u/ml
—
5
8
33
122
3.03
7.01
1.9
2.0
334.50
377.07
nmol/l
0.46
28
112
20
53
4.07
6.99
1.5
1.5
0.09
0.00
g/l
0.48
20
48
105
667
2.18
6.93
6.5
3.5
42.13
84.59
ng/l
0.41
80
491
90
538
2.20
6.93
3.1
3.2
2.34
2.35
mmol/l
0.16
81
469
75
417
2.26
6.89
2.0
1.5
18.87
20.86
nmol/l
0.55
68
351
80
457
2.23
6.88
5.2
3.0
0.57
0.38
e6/l
0.48
71
338
30
106
3.14
6.87
5.4
3.0
2.35
1.86
mmol/l
0.18
19
81
145
1053
2.29
6.76
5.7
4.3
—
3281.28
—
0
18
12
12
10.54
6.63
2.3
1.2
—
—
—
0
0
19
51
4.00
6.53
1.5
1.3
0.00
0.00
g/l
-0.00
19
46
17
43
4.22
6.30
5.1
1.9
23.89
24.92
mmol/l
0.28
17
43
16
30
5.69
5.98
5.6
2.1
17.14
16.31
%
—
10
14
17
45
4.03
5.94
2.0
1.6
—
—
—
0
0
17
46
3.94
5.77
2.0
1.6
—
—
—
0
0
21
67
3.38
5.65
1.5
1.5
7.85
7.31
g/l
0.47
21
60
21
67
3.38
5.65
1.5
1.5
—
—
—
0
0
19
57
3.57
5.60
1.5
1.3
36.42
37.05
g/l
0.17
19
50
97
636
2.00
5.52
6.2
3.7
—
—
—
0
0
20
63
3.41
5.48
1.5
1.5
9.78
10.82
g/l
0.72
20
55
107
728
1.98
5.46
3.3
2.6
—
—
—
0
0
20
64
3.35
5.35
1.5
1.5
3.56
3.11
g/l
0.96
20
57
15
32
4.97
5.10
2.0
1.7
—
—
—
0
0
50
264
2.18
5.03
4.2
2.7
3.42
1.84
e6/l
0.70
35
143
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
16
38
4.48
4.94
4.3
2.0
0.23
0.35
u/ml
1.03
11
21
53
289
2.12
4.91
4.0
2.6
0.82
0.99
e6/l
0.31
39
168
13
25
5.48
4.86
1.5
1.4
—
—
—
0
0
16
48
3.53
4.71
3.3
2.8
—
3.60
—
0
6
30
130
2.53
4.70
4.8
2.6
34.17
64.94
ml/min/173m2
6.83
18
51
13
27
5.07
4.58
1.9
1.5
—
—
—
0
0
14
32
4.62
4.53
2.0
1.4
—
—
—
0
0
13
29
4.71
4.33
1.7
1.4
—
—
—
0
0
35
173
2.23
4.10
4.9
3.4
—
—
—
0
0
14
36
4.10
4.08
2.1
1.4
—
—
—
0
0
51
294
1.98
4.01
1.4
1.2
0.67
1.65
u/ml
0.70
15
74
36
183
2.17
3.94
2.3
2.9
9.70
8.44
umol/l
0.19
30
162
185
1612
2.51
3.92
33.9
14.1
26.00
25.31
mg/l
0.12
174
1279
16
55
3.07
3.83
4.9
1.9
198.06
190.76
ug/l
0.06
16
50
13
34
4.01
3.77
1.4
1.5
346.71
260.07
ug/g
—
7
19
11
25
4.59
3.68
2.7
1.5
1.86
1.55
mmol/l
0.92
11
25
61
385
1.83
3.61
3.2
2.3
—
—
—
0
0
28
136
2.23
3.42
7.4
3.4
1.22
1.22
mmol/l
0.31
28
121
9
19
4.90
3.28
1.3
1.1
—
—
—
0
0
167
1433
1.89
3.16
5.7
4.4
2.05
1.95
mu/l
0.54
158
1272
127
1010
1.68
3.16
4.0
3.0
69.65
47.62
u/l
1.12
119
934
7
12
6.00
3.04
1.3
1.2
—
—
—
0
0
11
31
3.69
3.04
2.4
1.7
—
—
—
0
0
11
31
3.69
3.04
2.4
1.7
—
—
—
0
0
9
21
4.43
3.03
1.8
2.0
—
—
—
0
0
8
17
4.85
2.95
2.6
2.1
—
—
—
0
0
8
17
4.85
2.95
2.6
2.1
—
—
—
0
0
8
17
4.85
2.95
2.6
2.1
—
—
—
0
0
9
22
4.23
2.92
2.4
1.4
—
—
—
0
0
9
22
4.23
2.92
2.4
1.4
—
—
—
0
0
6
9
6.83
2.88
1.3
1.1
—
—
—
0
0
10
29
3.57
2.73
1.3
1.3
—
—
—
0
0
10
29
3.57
2.73
1.3
1.3
—
—
—
0
0
6
10
6.14
2.71
1.3
1.1
—
—
—
0
0
6
10
6.14
2.71
1.3
1.1
—
—
—
0
0
8
20
4.12
2.59
1.4
1.4
—
—
—
0
0
8
20
4.12
2.59
1.1
1.0
—
—
—
0
0
8
20
4.12
2.59
1.9
2.0
—
—
—
0
0
139
1162
1.61
2.57
4.8
3.6
15.08
14.96
pmol/l
0.24
124
1036
5
7
7.28
2.56
1.4
1.3
—
—
—
0
0
7
16
4.49
2.49
2.1
1.4
—
—
—
0
0
6
12
5.11
2.42
2.3
1.9
—
—
—
0
0
6
12
5.11
2.42
1.2
1.2
—
—
—
0
0
6
12
5.11
2.42
1.2
1.2
—
—
—
0
0
46
299
1.69
2.40
4.3
3.8
978.67
284.62
ng/l
0.36
40
235
25
134
1.99
2.39
3.6
3.4
459.44
196.34
ng/l
1.08
25
121
10
33
3.13
2.39
1.8
1.2
—
—
—
0
0
11
39
2.92
2.38
1.6
1.2
—
—
—
0
0
14
59
2.47
2.35
2.3
3.3
—
—
—
0
0
11
40
2.85
2.31
1.6
1.2
—
—
—
0
0
20
100
2.11
2.30
2.3
1.6
—
—
—
0
0
6
13
4.72
2.29
1.2
1.2
—
—
—
0
0
6
13
4.72
2.29
1.2
1.2
—
—
—
0
0
6
13
4.72
2.29
1.2
1.2
—
—
—
0
0
7
18
3.99
2.27
1.4
1.2
—
—
—
0
0
6
14
4.38
2.16
1.3
1.4
—
—
—
0
0
49
335
1.61
2.09
3.3
1.7
1.51
1.37
mg/l
0.17
36
258
14
63
2.31
2.06
1.6
1.3
—
—
—
0
0
35
222
1.70
1.99
21.9
6.9
—
—
—
0
0
5
11
4.63
1.95
1.2
1.0
—
—
—
0
0
5
11
4.63
1.95
1.2
1.0
—
—
—
0
0
59
430
1.52
1.90
2.0
1.7
1.72
1.30
mmol/l
2.40
54
357
9
34
2.72
1.89
1.2
1.6
—
—
—
0
0
31
193
1.71
1.88
4.1
4.6
3.05
60.00
ug/l
0.81
23
165
6
17
3.60
1.85
4.5
3.4
—
—
—
0
0
6
19
3.22
1.67
7.0
2.2
5.03
3.79
nmol/l
—
6
19
7
25
2.86
1.66
3.6
3.4
54.00
55.44
%
—
7
25
167
1518
1.54
1.61
9.3
5.7
43.33
39.80
mmol/mol
3.47
157
1395
7
26
2.75
1.59
1.1
1.3
—
—
—
0
0
47
341
1.49
1.53
2.0
1.7
508.49
436.26
pmol/l
0.71
41
280
11
51
2.22
1.53
1.4
1.9
—
—
—
0
0
5
15
3.39
1.53
1.2
1.1
350.00
312.47
pmol/l
—
5
15
24
148
1.70
1.52
1.7
2.0
1.72
1.47
%
0.48
18
130
185
1729
1.72
1.50
19.1
10.4
26.01
25.61
u/l
0.13
180
1666
9
37
2.50
1.50
2.2
1.3
—
—
—
0
0
5
17
2.99
1.36
1.0
1.0
—
1.33
—
0
6
5
17
2.99
1.36
2.8
2.2
—
—
—
0
0
8
35
2.34
1.28
1.3
1.4
—
—
—
0
0
6
25
2.44
1.25
1.0
1.1
—
—
—
0
0
8
37
2.21
1.23
1.8
1.3
—
—
—
0
0
5
19
2.67
1.22
1.2
1.2
—
—
—
0
0
10
50
2.05
1.18
2.9
1.9
—
—
—
0
0
98
840
1.32
1.16
3.1
2.6
—
—
—
0
0
7
32
2.23
1.09
1.0
1.5
249.00
256.63
e6/l
—
7
27
188
1794
1.58
1.00
50.0
20.9
38.62
40.39
%
2.95
171
1675
10
54
1.90
0.98
3.6
2.2
—
—
—
0
0
173
1633
1.38
0.90
6.6
4.9
2.45
2.73
mmol/l
3.62
161
1482
164
1540
1.32
0.84
5.4
3.9
1.74
1.25
mmol/l
8.56
149
1387
168
1587
1.32
0.79
5.9
4.3
1.27
1.45
mmol/l
5.84
155
1442
169
1599
1.32
0.78
6.0
4.4
4.31
4.61
mmol/l
2.96
157
1466
5
26
1.95
0.71
2.0
1.9
—
—
—
0
0
5
26
1.95
0.71
2.0
1.2
—
—
—
0
0
167
1585
1.29
0.69
6.0
4.7
6.44
5.99
mmol/l
3.03
151
1436
5
28
1.80
0.66
1.2
1.3
551.40
285.00
mu/l
—
5
28
5
29
1.74
0.64
1.2
1.5
—
—
—
0
0
28
221
1.31
0.59
5.0
4.5
28.19
32.52
%
1.60
21
149
5
88
0.56
0.57
1.6
2.1
—
—
—
0
0
11
73
1.54
0.57
2.1
3.5
22.64
1593.38
u/ml
0.50
11
61
84
762
1.17
0.50
4.4
5.3
2.50
2.78
ug/l
0.15
73
683
5
31
1.63
0.43
1.4
1.1
—
—
—
0
0
5
32
1.58
0.42
1.4
1.3
—
6.96
—
0
5
5
33
1.53
0.41
1.4
1.3
—
—
—
0
0
5
33
1.53
0.41
1.4
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
1.65
—
0
9
0
18
0.00
0.40
0.0
1.2
—
7.88
—
0
13
5
35
1.44
0.39
1.4
1.2
—
1.08
—
0
5
5
79
0.62
0.36
1.6
2.0
—
—
—
0
0
5
41
1.22
0.22
1.4
1.2
—
2.99
—
0
9
12
98
1.24
0.21
1.2
1.3
—
27.76
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
157
1535
1.10
0.19
30.6
13.3
64.74
77.49
ml/min/173m2
7.25
143
1300
7
67
1.05
0.08
1.3
1.0
—
—
—
0
0
22
209
1.06
0.04
1.6
1.5
—
—
—
0
0
61
620
0.98
0.02
4.2
4.7
22.09
21.01
%
0.26
35
322
44
447
0.98
0.01
3.3
3.1
0.74
0.72
ug/l
0.07
39
312
15
147
1.02
0.00
1.5
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
7.82
—
0
5
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
7.59
—
0
7
0
6
0.00
-0.00
0.0
2.7
—
212.83
—
0
6
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: E4_PURINEPYRI – Disorders of purine and pyrimidine metabolism
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).